A study published this month proposes that biosimilars be assessed in a quantitative benefit-risk analysis to assess whether what the authors call “uncertainty in the clinical performance of biosimilars” can be countered by lower pricing.
Development of biosimilars generally involves, as a culminating step, a confirmatory study in the most sensitive population in which the biosimilar is proposed for use. These confirmatory studies, which are undertaken after preclinical models have shown no differences between the biosimilar and its reference, and after pharmacokinetic and pharmacodynamic evaluation has been conducted, are intended to resolve any residual uncertainty that developers or regulators may have about the similarity of the proposed product and its reference. Developers then provide scientific justification to regulators for the extrapolation of indications to disease states other than the one studied in the confirmatory trial.
The extrapolation of indications means that fewer clinical data are available for a biosimilar’s use in some disease states at the time of its launch, and that fact has led some clinicians to voice concerns about using biosimilars in treating diseases in which they were not directly studied in a confirmatory trial. One stated concern related to biosimilars has been the potential risk for increased immunogenicity, though more than 10 years and 700 million patient days of experience with biosimilars have not yielded evidence of such a risk.1
A study published this month proposes that biosimilars be assessed in a quantitative benefit-risk analysis to assess whether “uncertainty in the clinical performance of biosimilars,” primarily with respect to a hypothetical immunogenicity risk, arising from the extrapolation of indications can be “countered by their lower pricing.”2
The paper, published in PharamcoEconomics, used a 1-year decision-analytic model developed for CT-P13 (Inflectra, Remsima), an infliximab biosimilar, for the treatment of Crohn disease (CD). According to the paper’s authors, immunogenicity is a special concern with infliximab in CD as opposed to other disease states.
The authors designed a model of 1-year cost-effectiveness from the UK National Health Service (NHS) perspective. A hypothetical cohort of new starts with moderate to severe CD was simulated through the model. Immunogenicity was a key modifier; the rate of development of antibodies to infliximab were derived from meta-analysis assessing the brand-name infliximab, Remicade. Costs were taken from a 2009 Markov model, adjusted for inflation, and from NHS reference costs.
The base-case analysis resulted in an expected 1-year quality-adjusted life-year (QALY) of 0.803 for both the biosimilar and for its reference, with expected 1-year costs of £18,087 (US $25,109) and £19,176 (US $26,620), respectively.
However, the authors write that, “assuming 50% of patients develop [antidrug antibodies, ADAs] for Inflectra, compared with 12.4% who develop [ADAs] from Remicade,” then the biosimilar would only remain the preferred infliximab option if it were priced below £410 (US $498) per vial, versus £420 (US $510) per vial for the reference. The authors also put forth what they call a worst-case scenario in which 100% of patients exposed to the biosimilar develop ADAs, in which case the price for the biosimilar would need to drop to £395 (US $480) per vial to remain a preferred treatment. (However, the authors acknowledge that a recent head-to-head study of CT-P13 versus its reference in patients with CD, published in The Lancet, did not show any difference between the biosimilar and its reference in the population of patients with CD.3)
According to the current study’s authors, their model provides a basis for the quantitative evaluation of biosimilars to support health technology assessments, and can be used to “protect health systems” from “potential risks of biosimilars” when indications are extrapolated.
References
1. Cohen HP, Blauvelt A, Rifkin RM, Danese S, Gokhale SB, Woollett G. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. [Published online March 3, 2018] Drugs. doi: 10.1007/s40265-018-0881-y.
2. Catt H, Bodger K, Kirkham JJ, Hughes DA. Value assessment and quantitative benefit-risk modelling of biosimilar infliximab for Crohn’s disease [published online August 2, 2019]. PharamcoEconomics. doi: 10.1007/s40273-019-00826-0.
3. Ye BD, Pesegova M, Alexeeva O, Osipenko M, Lahat A, Dorofeyev A. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study [published online, March 28, 2019]. Lancet. doi: 10.1016/S0140-6736(18)32196-2.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.